Skip to main content
Have a personal or library account? Click to login
5-HTTLPR polymorphism and anxious preoccupation in early breast cancer patients Cover

5-HTTLPR polymorphism and anxious preoccupation in early breast cancer patients

Open Access
|Nov 2012

References

  1. 1. Stanton AL, Danoff-Burg S, Huggins M. The first year after breast cancer diagnosis: hope and coping strategies as predictors of adjustment.2002;93-102.
  2. 2. Ozalp E, Soygu H, Cankurtaran E, Turhan L, Akbyk D, Geyik P. Psychiatric morbidity and its screening in Turkish women with breast cancer: a comparison between the HADS and SCID tests.2008;668-75. Lueboonthavatchai P. Prevalence and psychosocial factors of anxiety and depression in breast cancer patients.2007;2164-74.
  3. 3. Boehmke MM, Dickerson SS. The diagnosis of breast cancer: transition from health to illness.2006,1121-7.
  4. 4. Fertig DL. Depression in patients with breast cancer: prevalence, diagnosis, and treatment.1997;292-302.
  5. 5. Holland JC, Mastrovito R. Psychologic adaptation to breast cancer.1980;1045-52.
  6. 6. Akechi T, Okuyama T, Imoto S, Yamawaki S, Uchitomi Y. Biomedical and psychosocial determinants of psychiatric morbidity among postoperative ambulatory breast cancer patients.2001;195-202.
  7. 7. Matsuoka Y, Nakano T, Inagaki M, Sugawara Y, Akechi T, Imoto S, et al. Cancer-related intrusive throughs as an indicator of poor psychological adjustment at 3 or more years after breast surgery: a preliminary study.2002;117-24.
  8. 8. Cordova MJ, Giese-Davis J, Golant M, Kronnenwetter C, Chang V, Mc Farlin S, et al. Mood disturbance in community cancer support groups. The role of emotional suppression and fighting spirit.2003;461-7.
  9. 9. Grassi L, Buda P, Cavana L, Annunziata MA, Torta R, Varetto A. Styles of coping with cancer: The Italian version of the Mini-Mental Adjustment to Cancer (Mini-Mac) scale.2005;115-24.
  10. 10. Grassi L, Travado L, Moncayo FLG, Sabato S, Rossi E and the SEPOS group. Psychosocial morbidity and its correlates in cancer patients of the Mediterranean area: findings from the Southern European Psycho-Oncology Study.2004;243-8.
  11. 11. Bloom JR, Stewart SL, Johnston M, Banks P, Fobair P. Sources of support and the physical and mental well being of young women with breast cancer.2001;1513-24.
  12. 12. Greer S, Morris T, Pettingale KW. Psychological response to breast cancer: effect on outcome.1979;785-7.
  13. 13. Watson M, Haviland JS, Greer S, Davidson J, Bliss JM. Influence of psychological response on survival in breast cancer: a population-based cohort study.1999;1331-6.
  14. 14. Erculj N, Kovac V, Hmeljak J, Dolzan V. The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma.2012;461-7.
  15. 15. Erčulj N, Kovač V, Hmeljak J, Franko A, Dodič-Fikfak M, Dolžan V. The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma.2012;58-68.
  16. 16. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene.2003;386-9.
  17. 17. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region.1996;1527-31.
  18. 18. Plesnicar A, Golicnik M, Fazarinc IK, Kralj B, Kovac V, Plesnicar BK. Attitudes of midwifery students towards teaching brast-self examination.2010;52-6.
  19. 19. Ovcaricek T, Frkovic SG, Matos E, Mozina B, Borstnar S. Triple negative breast cancer - prognostic factors and survival.2011;46-52.
  20. 20. Andersen B, William B, Farrar WB, Golden-Kreutz D, Kutz LA, Courtney ME, et al. Stress and immune responses after surgical treatment for regional breast cancer.1998;30-6.
  21. 21. Zalsman G, Huang Y, Oquendo MA, Burke AK, Hu X, Brent DA, et al. Association of a triallelic serotonin transporter gene promoter region (5-HTTLPR) polymorphism with stressful life events and severity of depression.2006;1588-93.
  22. 22. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder.2006;815-26.
  23. 23. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale.1983;361-70.
  24. 24. Garcia-Cebrian A, Bauer M, Montejo AL, Dantchev N, Demyttenaere K, Gandhi P, et al. Factors influencing depression endpoints research (FINDER): Study design and population characteristics.2008;57-65.
  25. 25. Gelernter J, Kranzler H, Cubbels JF. Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African and European-American and Japanese populations and in alcohol-dependent subjects.1997;243-6.
  26. 26. Risch N, Herrell R, Lehner T, Liang KY, Eaves L, Hoh J, et al. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis.2010;2462-71.
  27. 27. Munafò MR, Freimer NB, Ng W, Ophoff R, Veijola J, Miettunen J, et al. 5-HTTLPR genotype and anxiety-related personality traits: a meta-analysis and new data.2009;271-81.
  28. 28. Middeldorp CM, de Geus EJ, Willemsen G, Hottenga JJ, Slagboom PE, Boomsma DI. The serotonin transporter gene length polymorphism (5-HTTLPR) and life events: no evidence for an interaction effect on neuroticism and anxious depressive symptoms.2010;544-9.
  29. 29. Karg K, Burmeister M, Shedden K, Sen S. The Serotonin Transporter Promoter Variant (5-HTTLPR), Stress, and Depression Meta-analysis Revisited: Evidence of Genetic Moderation.2011;444-54.
  30. 30. Grassi L, Rossi E, Cobianchi M, Aguiari L, Capozzo MA, et al. Depression and serotonin transporter (5-HTTLPR) polymorphism in breast cancer patients.2010;346-50.
  31. 31. Kash KM, Mago R, Kunkel E. Psychosocial oncology: supportive care for the cancer patients.2004;211-8.
  32. 32. Ho SM, Fung WK, Chan CL, Watson M, Tsui YK. Psychometric properties of the Chinese version of the Mini-Mental Adjustment to Cancer (MINIMAC) scale.2003;547-56.
  33. 33. Anagnostopoulos F, Kolokotroni P, Spanea E, Chryssochoou M. The minimental adjustment to cancer (mini-MAC) scale: construct validation with a Greek sample of breast cancer patients.2006;79-89.
  34. 34. Capozzo MA, Martinis E, Pellis G, Giraldi T. An early structured psychoeducational intervention in breast cancer patients: results from a feasibility study.2010;228-34.
  35. 35. Fawzy FI, Fawzy NW. A structured psychoeducational intervention for cancer patients.1994;149-52.
  36. 36. Carver CS, Pozo C, Harris SD. How coping mediates the effect of optimism on distress: A study of women with early stage breast cancer.1993;375-90.
  37. 37. Osowiecki D, Compas BE. Psychological adjustment to cancer: Control beliefs and coping in adult cancer patients.1998;483-99.
  38. 38. Stanton AL, Danoff-Burg S, Cameron CL. Emotionally expressive coping predicts psychological and physical adjustment to breast cancer.2000;875-82.
  39. 39. Roth S, Cohen LJ. Approach, avoidance, and coping with stress.1986;813-9.
  40. 40. Fukui S, Kugaya A, Okamura H, Kamiya M, Koike M, Nakanishi T, et al. A psychosocial group intervention for Japanese women with primary breast cancer: a randomized controlled trial.2000;1026-36.
  41. 41. Weis J. Support groups for cancer patients.2003;763-8.
  42. 42. Kissane D, Bloch S, Smith GC, Miach P. Cognitive-existential group psychotherapy for women with primary breast cancer: a randomised controlled trial.2003;532-46.
  43. 43. Maeda T, Kurihara H, Morishima I, Munakata T. The effect of psychological intervention on personality change, coping, and psychological distress of Japanese primary breast cancer patients.2008;27-35.
  44. 44. Smits K, Smits L, Peeters F, Schouten J, Janssen R, Smeets H, et al. Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors.2007;137-43.
  45. 45. Schillani G, Capozzo MA, Aguglia E, De Vanna, M, Grassi L, Conte MA, et al. 5-HTTLPR polymorphism of serotonin transporter and effects of sertraline in terminally ill cancer patients: report of eleven cases.2008;563-7.
  46. 46. Capozzo MA, Schillani G, Aguglia E, De Vanna M, Grassi L, Conte MA, et al. Serotonin transporter 5-HTTLPR polymorphism and response to citalopram in terminally ill cancer patients: report of twenty-one cases.2009;479-83.
  47. 47. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder.2010;473-500.
  48. 48. Bandelow B, Andersen HF, Dolberg OT. Escitalopram in the treatment of anxiety symptoms associated with depression.2007;53-6.
  49. 49. Cankurtaran ES, Ozalp E, Soygur H, Akbiyik DI, Turhan L, Alkis N. Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine.2008;1291-8.
  50. 50. Caraci F, Crupi R, Drago F, Spina E. Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract.2011;570-7.
  51. 51. Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study.2010;c693.
  52. 52. In brief: Tamoxifen and SSRI interaction.. 2009;45
DOI: https://doi.org/10.2478/v10019-012-0024-0 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 321 - 327
Submitted on: Oct 15, 2011
Accepted on: Feb 2, 2012
Published on: Nov 9, 2012
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2012 Giulia Schillani, Daniel Era, Tania Cristante, Giorgio Mustacchi, Martina Richiardi, Luigi Grassi, Tullio Giraldi, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.